Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C

Digestive and Liver Disease

Volumn 46, Issue 8, 2014, Pages 738-743

  Atsukawa, Masanori ^a   Tsubota, Akihito ^b   Shimada, Noritomo ^c   Abe, Hiroshi ^d   Kondo, Chisa ^a   Itokawa, Norio ^a   Nakagawa, Ai ^a   Iwakiri, Katsuhiko ^a   Kawamoto, Chiaki ^e   Aizawa, Yoshio ^d   Sakamoto, Choitsu ^e  

^a NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Shinmatsudo Central General Hospital   (Japan)

^d Jikei University Katsushika Medical Center   (Japan)

^e NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Hepatitis C virus; Pegylated interferon; Telaprevir

Indexed keywords

CALCIFEDIOL; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; TELAVIC; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; OLIGOPEPTIDE; RECOMBINANT PROTEIN; VIRUS RNA;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; FEMALE; GENE; GENOTYPE; HEPATITIS C; HUMAN; INTERLEUKIN 28B GENE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL; ADOLESCENT; BLOOD; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; PROSPECTIVE STUDY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CALCIFEDIOL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904733489     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.05.004     Document Type: Article

References (36)

1. McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New England Journal of Medicine 2009, 360:1827-1838.
2. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine 2011, 364:2405-2416.
3. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. New England Journal of Medicine 2011, 364:2417-2428.
4. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine 2011, 364:1195-1206.
5. Kumada H., Toyota J., Okanoue T., et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. Journal of Hepatology 2012, 56:78-84.
6. Hayashi N., Okanoue T., Tsubouchi H., et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. Journal of Viral Hepatitis 2012, 19:e134-e142.
7. Chayama K., Hayes C.N., Abe H., et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. Journal of Infectious Diseases 2011, 204:84-93.
8. Akuta N., Suzuki F., Hirakawa M., et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010, 52:421-429.
9. Tsubota A., Shimada N., Atsukawa M., et al. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b. Journal of Gastroenterology and Hepatology 2014, 29:144-150.
10. Ogawa E., Furusyo N., Nakamuta M., et al. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. Alimentary Pharmacology and Therapeutics 2013, 38:1076-1085.
11. Shimada N., Tsubota A., Atsukawa M., et al. alpha-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype. Journal of Medical Virology 2014, 86:461-472.
12. Gordon S.C., Yoshida E.M., Lawitz E.J., et al. Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin. Alimentary Pharmacology and Therapeutics 2013, 38:16-27.
13. Akuta N., Suzuki F., Sezaki H., et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005, 48:372-380.
14. Akuta N., Suzuki F., Kawamura Y., et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. Journal of Medical Virology 2007, 79:1686-1695.
15. McHutchison J.G., Manns M., Patel K., et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061-1069.
16. Shiffman M.L., Ghany M.G., Morgan T.R., et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007, 132:103-112.
17. Hiramatsu N., Oze T., Yakushijin T., et al. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. Journal of Viral Hepatitis 2009, 16:586-594.
18. Enomoto N., Sakuma I., Asahina Y., et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. Journal of Clinical Investigation 1995, 96:224-230.
19. Enomoto N., Sakuma I., Asahina Y., et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. New England Journal of Medicine 1996, 334:77-81.
20. Bitetto D., Fattovich G., Fabris C., et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011, 53:1118-1126.
21. Falleti E., Bitetto D., Fabris C., et al. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology 2012, 56:1641-1650.
22. Gal-Tanamy M., Bachmetov L., Ravid A., et al. Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology 2011, 54:1570-1579.
23. Matsumura T., Kato T., Sugiyama N., et al. 25-Hydroxyvitamin D3 suppresses hepatitis C virus production. Hepatology 2012, 56:1231-1239.
24. Holick M.F., Vitamin D. Deficiency. New England Journal of Medicine 2007, 357:266-281.
25. Kozawa K., Imawari M., Shimazu H., et al. Vitamin D status after total gastrectomy. Digestive Diseases and Sciences 1984, 29:411-416.
26. Imawari M., Akanuma Y., Itakura H., et al. The effects of diseases of the liver on serum 25-hydroxyvitamin D and on the serum binding protein for vitamin D and its metabolites. Journal of Laboratory and Clinical Medicine 1979, 93:171-180.
27. Petta S., Camma C., Scazzone C., et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010, 51:1158-1167.
28. Kankova M., Luini W., Pedrazzoni M., et al. Impairment of cytokine production in mice fed a vitamin D3-deficient diet. Immunology 1991, 73:466-471.
29. Morel P.A., Manolagas S.C., Provvedini D.M., et al. Interferon-gamma-induced IA expression in WEHI-3 cells is enhanced by the presence of 1,25-dihydroxyvitamin D3. Journal of Immunology 1986, 136:2181-2186.
30. Manuel Quesada J., Solana R., Serrano I., et al. Immunologic effects of vitamin D. New England Journal of Medicine 1989, 321:833-834.
31. Bitetto D., Fabris C., Fornasiere E., et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transplant International 2011, 24:43-50.
32. Kitson M.T., Dore G.J., George J., et al. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. Journal of Hepatology 2013, 58:467-472.
33. 3 levels affect treatment outcome in pegylated-interferon/ribavirin combination therapy for compensated cirrhotic patients with HCV genotype 1b and high viral load. Hepatology Research 2014, Jan 14, [Epub ahead of print].
34. Zeuzem S., Berg T., Gane E., et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014, 146:430-441.
35. Hayashi N., Seto C., Kato M., et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. Journal of Gastroenterology 2013, 49:138-147.
36. Atsukawa M., Tsubota A., Shimada N., et al. Efficacy of alfacarcidol on peg-IFN/ribavirin combination therapy for elderly patients with chronic hepatitis C: a pilot study. Hepatitis Monthly 2013, 13:e14872.